Articles

It is true that some branches of academic economics sometimes value theoretical insights and technical details over pragmatic results that can be broadly applied. However, most of the core insights of economic analysis tend to be accessible and have highly pragmatic implications.

An interview with Brian Sweet, RPh, MBA

Prostate cancer patients have 2 new therapeutic options this summer with the approvals of sipuleucel-T and cabazitaxel. The former drug is an important scientific advance as one of the pioneering cancer vaccines to show a prolongation of survival.

Sipuleucel-T (Provenge) and cabazitaxel (Jevtana) have drawn much attention both for being the first new treatments for advanced prostate cancer since docetaxel (Taxotere) was approved in 2004, and for their high costs. As described in Dr Newcomer’s accompanying piece, they will add significantly to the cost of care for prostate cancer patients.